A detailed history of Gateway Investment Advisers LLC transactions in Incyte Corp stock. As of the latest transaction made, Gateway Investment Advisers LLC holds 3,930 shares of INCY stock, worth $293,964. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,930
Previous 4,296 8.52%
Holding current value
$293,964
Previous $260,000 0.38%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

SELL
$57.33 - $68.61 $20,982 - $25,111
-366 Reduced 8.52%
3,930 $259,000
Q2 2024

Jul 12, 2024

BUY
$51.18 - $63.75 $35,928 - $44,752
702 Added 19.53%
4,296 $260,000
Q1 2024

Apr 12, 2024

BUY
$56.55 - $66.59 $203,240 - $239,324
3,594 New
3,594 $204,000
Q3 2019

Oct 15, 2019

SELL
$72.82 - $86.52 $495,321 - $588,509
-6,802 Closed
0 $0
Q2 2019

Jul 17, 2019

SELL
$73.52 - $88.7 $19,997 - $24,126
-272 Reduced 3.85%
6,802 $578,000
Q1 2019

Apr 10, 2019

SELL
$63.56 - $88.17 $24,788 - $34,386
-390 Reduced 5.23%
7,074 $608,000
Q4 2018

Jan 14, 2019

BUY
$58.5 - $69.94 $3,627 - $4,336
62 Added 0.84%
7,464 $475,000
Q3 2018

Oct 16, 2018

SELL
$61.75 - $74.23 $58,662 - $70,518
-950 Reduced 11.37%
7,402 $511,000
Q2 2018

Jul 11, 2018

SELL
$60.85 - $83.98 $58,841 - $81,208
-967 Reduced 10.38%
8,352 $560,000
Q1 2018

Apr 12, 2018

SELL
$83.06 - $100.98 $37,293 - $45,340
-449 Reduced 4.6%
9,319 $777,000
Q4 2017

Jan 17, 2018

SELL
$93.56 - $116.6 $90,659 - $112,985
-969 Reduced 9.02%
9,768 $925,000
Q3 2017

Oct 16, 2017

BUY
$109.15 - $138.27 $1.17 Million - $1.48 Million
10,737
10,737 $1.25 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16.6B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Gateway Investment Advisers LLC Portfolio

Follow Gateway Investment Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gateway Investment Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gateway Investment Advisers LLC with notifications on news.